Pembrolizumab with low-dose carboplatin for recurrent platinum-resistant ovarian, fallopian tube, and primary peritoneal cancer: survival and immune correlates
Enregistré dans:
Auteurs principaux: | Mary L Disis, John B Liao, Doreen M Higgins, Jennifer S Childs, Sasha E Stanton, Anna V Tinker, William R Gwin, Renata R Urban, Katie M Hitchcock-Bernhardt, Andrew L Coveler, Hania N Shakalia, Ron E Swensen, Tanya A Wahl, Richard G Ancheta, Kathryn F McGonigle, James Y Dai, Barbara A Goff |
---|---|
Format: | article |
Langue: | EN |
Publié: |
BMJ Publishing Group
2021
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/fa0344d0725b4c7788695fafcc3f18e8 |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Real-world outcomes of first-line pembrolizumab plus pemetrexed-carboplatin for metastatic nonsquamous NSCLC at US oncology practices
par: Vamsidhar Velcheti, et autres
Publié: (2021) -
High grade serous ovarian carcinomas originate in the fallopian tube
par: S. Intidhar Labidi-Galy, et autres
Publié: (2017) -
The Role of Universities and Law Schools in Documenting Serious International Crimes and Advancing the Rule of Law
par: Brianne McGonigle Leyh
Publié: (2021) -
Comparative study analyzing survival and safety of bevacizumab/carboplatin/paclitaxel versus carboplatin/docetaxel in initial treatment of metastatic Her-2-negative breast cancer
par: Abdel Kader Y, et autres
Publié: (2013) -
Effects of long-term norepinephrine treatment on normal immortalized ovarian and fallopian tube cells
par: Sweta Dash, et autres
Publié: (2021)